Overview of Doral Tablets

This foundational section provides a concise overview of the identity, composition, and general purpose of Doral Tablets, strictly adhering to high-level classification and definitions.

Property	Description
Active Ingredient	Quazepam (INN)
Form	Tablet (Oral Route)
Pharmacological Class	Benzodiazepine / Sedative-Hypnotic
Common Use	Treating Insomnia (Sleep Aid)
Origin	Synthetic Compound

What is Doral Tablets and Its Active Ingredient (Quazepam)?

Doral Tablets are the brand name for the medication containing the single active ingredient, Quazepam (INN). This substance is a synthetic compound and belongs to the chemical class of trifluoroethyl benzodiazepines. The medication is supplied as an oral tablet, and as a prescription-only (Rx) medicine, its use is strictly overseen by a healthcare professional. Unlike some sleep aids designed for short-term effects, Quazepam is often recognized for its longer duration of action, which supports patients who have difficulty maintaining sleep through the entire night.

Is Doral a Benzodiazepine Sedative-Hypnotic?

Yes, Doral belongs to the benzodiazepine drug class, which is further categorized as a sedative-hypnotic agent. This classification defines its core mechanism: it works by amplifying the effects of GABA (gamma-aminobutyric acid), the brain's primary inhibitory chemical. This action produces a powerful, yet targeted calming effect on the central nervous system. This property is fundamental to its role as a sleeping medication.

What is the General Purpose of This Sleep Aid?

The primary purpose of Doral Tablets is the treatment of insomnia, helping adults who struggle with sleep difficulties. It functions as a potent sleep aid to both help individuals fall asleep and support sleep maintenance throughout the night. The medicine is clinically recognized for its ability to both induce and sustain sleep, addressing the over-activity in the brain that often prevents restful sleep, making it a suitable choice when a longer-lasting sedative action is required.

What side effects are possible with Doral Tablets?

Safety Risks and Adverse Reactions

Doral (quazepam) is classified as a Schedule IV controlled substance due to documented risks of abuse, misuse, addiction, and the potential for physical dependence. Abrupt discontinuation or rapid dose reduction following continued use may lead to acute, life-threatening withdrawal reactions, which require a gradual tapering to mitigate.

Serious Safety Restrictions and Warnings

Official regulatory information includes a Boxed Warning regarding the serious risks associated with the concomitant use of Doral and opioid medications. This combination can result in profound sedation, severe respiratory depression, coma, and death.

Clinically significant, severe adverse reactions include rare cases of anaphylactic and anaphylactoid reactions, such as angioedema (swelling) involving the tongue, glottis, or larynx, which can cause fatal airway obstruction. Patients who experience such reactions are advised to not be re-exposed to the drug.

Common and Behavioral Side Effects

Doral is a central nervous system (CNS) depressant. The most common adverse reactions reported in clinical trials (incidence >1%) are: drowsiness, headache, fatigue, dizziness, dry mouth, and dyspepsia (upset stomach).

Other serious documented safety issues involve abnormal thinking and complex behaviors while not fully awake, with subsequent amnesia for the event. These behaviors can include 'sleep-driving,' making phone calls, or preparing and eating food. The risk of these events is increased by higher doses or co-administration with other CNS depressants, including alcohol. Worsening of depression or suicidal thinking has also been reported with the use of sedative-hypnotics.

Population-Specific Considerations

The drug is contraindicated in patients with known hypersensitivity to quazepam or other benzodiazepines, established or suspected sleep apnea, or pulmonary insufficiency. Elderly and debilitated patients may be more sensitive to the CNS depressant effects, increasing the risk of falls and injury.

Overdose and Emergency Response

Doral Tablets overdose manifestations are officially documented as symptoms of Central Nervous System (CNS) depression, ranging from mild to potentially life-threatening. The documented presentations include drowsiness, confusion, ataxia, and dysarthria (slurred speech) in less severe scenarios, which may progress to coma in more serious cases.

Life-Threatening Risks and Emergency Action

The most serious outcomes documented in regulatory labeling are respiratory depression and death, risks significantly elevated when Quazepam is taken alongside other CNS depressants, particularly alcohol or opioid medications. Because of this, official guidance states that individuals must seek emergency medical attention immediately if an overdose is suspected or if signs of extreme sleepiness, shallow breathing, or breathing cessation occur.

Management and Monitoring

Management of Quazepam overdose is primarily symptomatic and supportive. Regulatory documents advise monitoring for continuous signs of sedation and respiratory compromise. The use of the reversal agent Flumazenil is noted but is generally not recommended for routine use, as its administration may precipitate seizures. Elderly and debilitated patients are noted in official labeling as being potentially more sensitive to the CNS depressant effects.

Therapeutic Uses of Doral Tablets

Quick Facts: Uses of Doral Tablets

Therapeutic Domain	Primary Focus
Insomnia	Difficulty with sleep onset and maintenance
Symptom Relief	Nocturnal and early morning awakenings

Doral Tablets (quazepam) are indicated for the management of insomnia, a condition characterized by disruptions in the sleep cycle. Healthcare professionals prescribe this medication to provide relief for specific sleep difficulties.

This medicine is authorized to address the challenge of falling asleep and may assist in promoting sleep continuity through the night. It is further used to mitigate the occurrence of frequent waking episodes during the night and premature waking in the early morning hours, which are associated with the symptoms of insomnia.

The use of Doral is generally considered for short-term therapeutic regimens to manage these symptoms as they manifest.

Eligibility and Restrictions for Use

Doral Tablets are primarily intended for use by adults for the management of insomnia. Official regulatory documents define strict eligibility criteria, classifying certain groups as absolutely prohibited, conditionally restricted, or having use not yet established.

The medicine is contraindicated in patients with a known hypersensitivity to quazepam or other benzodiazepines. Absolute non-eligibility rules also apply to patients with established or suspected sleep apnea and those with chronic pulmonary insufficiency, due to the risk of respiratory depression.

Quazepam is contraindicated during pregnancy due to the potential for fetal harm. Furthermore, use is not recommended for nursing mothers as the drug and its metabolites are known to be excreted in human milk. Safety and effectiveness have not been established in pediatric patients.

Use requires caution in specific populations, including older adults, who have an increased risk of falls and are more sensitive to the drug's effects. Caution is also necessary for patients with a history of substance abuse or dependence, depressive disorders, or impaired hepatic or renal function, as regulatory data regarding safety and efficacy are not established for these groups.

What should I know about interactions with other medicines?

Doral Tablets (quazepam) interacts with several medicinal products and substances, as documented in regulatory labeling. The most significant concern involves pharmacodynamic potentiation when co-administered with Opioids. This combination carries an official risk of profound sedation, respiratory depression, coma, and death, and must only be reserved for use when alternative treatment options are inadequate, requiring strict limitations on dosage and duration.

Other Central Nervous System (CNS) Depressants, including tricyclic antidepressants and other benzodiazepines, also exhibit additive depressant effects, which can potentially impair daytime function. For this reason, co-administration with other sedative-hypnotics is formally not recommended by regulatory authorities.

A separate pharmacokinetic interaction exists where quazepam functions as a CYP2B6 mechanism-based inhibitor. This action may result in increased plasma concentrations of any co-administered drugs that are substrates of the CYP2B6 enzyme.

Regarding other substances, Alcohol (Ethanol) should generally not be used during treatment due to the increased risk of additive CNS depression. Furthermore, a population-specific note highlights that Geriatric Patients may experience enhanced interaction potential with psychoactive drugs due to the prolonged half-life and subsequent accumulation of the active metabolite, N-desalkyl-2-oxoquazepam.

Mechanism of Action

The mechanism of Doral Tablets centers on its action as a Positive Allosteric Modulator (PAM) of the GABAA receptor complex, the central nervous system's main inhibitory signaling control. By binding to a specific allosteric site on the receptor, the molecule amplifies the effect of the endogenous neurotransmitter GABA, causing a higher frequency of chloride ion channel opening. This Cl^- influx electrically stabilizes, or hyperpolarizes, the neuron, which reduces its ability to fire and propagate excitatory signals.

Quazepam exhibits high functional selectivity for GABAA receptor subtypes containing the alpha1 subunit. This targeted action focuses the inhibitory effect on specific neural pathways involved in CNS arousal. Furthermore, the mechanism is sustained by active metabolites which continue to modulate the GABAA system, contributing to the prolonged suppression of CNS excitability and maintaining the stabilized inhibitory state for an extended duration.

Dosage and Administration Information

How to Use Doral Tablets: Official Administration Guidelines

Doral Tablets, which contain the active ingredient Quazepam, are administered exclusively via the oral route. The primary principle governing its use is adherence to the prescribed dosing schedule, frequency, and duration limits.

Labeled Dosing and Frequency

Quazepam is designated for once-daily use, taken at night immediately before going to bed. The standard regimen begins with a typical initial dose of 7.5 mg. Depending on the clinical scenario and the patient's response, the dosage may be adjusted up to a maximum of 15 mg per day. The tablets are functionally scored, allowing the 15 mg tablet to be split to achieve the 7.5 mg dose, in line with the principle of using the lowest effective amount.

Administration Conditions and Duration

The medicine should only be taken when the patient has the opportunity to get a full night’s sleep, generally defined as seven to eight hours, before the expected time of waking. This is a key procedural condition tied to proper administration. Doral is specifically intended for short-term use to manage insomnia symptoms. If the medication is to be reduced or discontinued, a gradual taper pattern is used to minimize discontinuation effects.

For older adults and debilitated patients, treatment is typically initiated at the lower end of the dosing range (7.5 mg). Safety and efficacy for use in pediatric patients have not been established.

Recent Clinical Evidence

Research evidence / Overview of Studies for Doral Tablets

Evidence for Use in Insomnia

This section summarizes the types of foundational research, including Randomized Controlled Trials (RCTs) and Placebo-Controlled Studies, that examined measurements related to difficulty falling asleep and those related to sleep maintenance. The primary research approach has been controlled clinical studies in which individuals with insomnia were observed in different research settings. The evidence primarily was studied for short-term symptom patterns in adults whose conditions were characterized by acute or disruptive episodes of poor sleep. Studies focused on episodes where symptoms become more noticeable, contributing to the contextualization of how patients reported their experience during these defined time intervals. Research describes patterns measured during the study period when compared to placebo.

Study Endpoints: How Sleep Was Measured in Trials

This part details the key metrics used by researchers to assess the drug in clinical evaluations, covering both objective measurements and subjective patient-reported measures. To gather objective information, studies utilized specialized Polysomnographic (Sleep Lab) Studies. These reports documented measurements related to objective Sleep Latency (the time it takes to fall asleep) and objective Total Sleep Time. Furthermore, research examined outcomes related to sleep maintenance, such as the total time a person spent awake after initially falling asleep. Alongside these lab measurements, research explored patient-reported outcomes describing perceived discomfort, including subjective ratings of sleep quality and the self-reported frequency of Nocturnal Awakenings.

Intermediate-Term Follow-up and Sustained Evidence

This section outlines the duration of the longest controlled trials conducted and describes the research structure used to study sustained patterns over several weeks of continuous administration. While much of the evidence was observed in short-term trials lasting just 5 to 7 nights, some research protocols extended to intermediate-term durations of up to 28 nights. These longer studies were used in research exploring how symptoms change over time and how sleep patterns were observed in the study populations during continuous use. These findings describe patterns observed across defined time intervals, but evidence remains limited regarding extended long-term data.

Evidence in Specialized Adult Populations

This part summarizes the specific research that has been conducted in patient groups other than the general adult population, including studies available for Geriatric/Elderly Adults and Psychiatric Outpatients with comorbid insomnia. Research examined specific trials involving Geriatric/Elderly Adults to understand how the medication was observed in that age group. Additionally, the evidence base includes studies where the medication was observed in Adult Psychiatric Outpatients whose conditions were characterized by insomnia. Findings from these research efforts contribute to understanding symptom patterns in these specialized groups, though results apply only to the populations studied.

Research Gaps and Unanswered Questions

This final section synthesizes the areas where regulatory and scientific literature indicates that data are still emerging or insufficient, specifically regarding the need for robust evidence on long-term efficacy and sustained use beyond short-term protocols. The available research includes limited follow-up durations, and there is limited information for long-term outcomes for continuous use. Existing studies provide limited insight into the long-term changes that may occur beyond the 28-day window. Consequently, certainty remains low regarding the use of Doral Tablets for chronic or extended therapeutic regimens, and regulatory documentation notes that efficacy for prolonged administration is not fully established.

Key Studies & References

Meta-analysis of benzodiazepine use in the treatment of insomnia (Holbrook AM, Crowther R, et al.)

Frequently Asked Questions (FAQ)

Common questions about Doral Tablets (FAQ)

Q: Can Doral Tablets be taken with other prescription medications?

A: Official documents warn that taking Doral Tablets alongside other Central Nervous System (CNS) depressants, such as opioids, tricyclic antidepressants, and other benzodiazepines, carries a risk of severe interaction. These combinations can potentially lead to profound sedation and respiratory problems. The regulatory documents do not provide a rule that covers all possible prescription medications.

Q: Are there any known interactions between Doral Tablets and herbal supplements?

A: While specific details on every supplement are not provided in the official labeling, the Medication Guide includes information advising patients to discuss all medicines, vitamins, and herbal supplements with their healthcare provider due to the potential for unforeseen interaction risks.

Q: Can Doral Tablets be used by people with liver disease?

A: Official information suggests caution when the medicine is administered to patients with hepatic, or liver, impairment. Because the safety and effectiveness of the drug have not been fully established in this group, official guidance highlights the need for monitoring signs of overdose in this population.

Q: Is it safe to use Doral Tablets during pregnancy or while breastfeeding?

A: Regulatory documents state that the safety of Doral Tablets has not been established for use during pregnancy. It is generally not recommended for use by nursing mothers because the active ingredient and its breakdown products are known to be present in human milk.

Q: Is Doral Tablets a sleeping pill or a muscle relaxer?

A: Doral Tablets are officially classified as a benzodiazepine hypnotic agent. Hypnotics are a class of medicine primarily used to help manage symptoms of insomnia, meaning it is classified as a sleeping pill.

Q: How long does it typically take to feel the effect of Doral Tablets?

A: Pharmacokinetic data from regulatory information describes a half-life of absorption of approximately 30 minutes. The medicine reaches its peak concentrations in the blood around two hours after administration.

Q: Is there a generic version of Doral Tablets available?

A: Yes, the active ingredient in Doral Tablets, known as quazepam, is available as a generic medication.

Q: What is the recommended storage temperature for Doral Tablets?

A: Official labeling specifies that Doral Tablets should be stored at controlled room temperature. This temperature is generally defined as being between 20 C and 25 C (68 F and 77 F).

Q: Is Doral Tablets appropriate for people who have kidney issues?

A: Regulatory information advises caution when the medicine is administered to patients with renal, or kidney, impairment. Since the safety and effectiveness of the drug have not been fully established in this group, official guidance highlights the need for monitoring signs of overdose in this population.

Q: Is Doral Tablets used for treating other conditions besides its main approved use?

A: The official labeling defines the specific condition for which the medicine is approved and prescribed. Regulatory documents state that this medicine should only be used for the condition for which it was prescribed.

Q: Is Doral Tablets ever prescribed for children or adolescents?

A: Regulatory documents state that the safety and effectiveness of Doral Tablets have not been established in the pediatric population, which includes children and adolescents.

Q: Do Doral Tablets come in different strengths?

A: The tablets are currently supplied in a 15 mg strength. This tablet is functionally scored (designed to be split) to allow for the administration of the 7.5 mg dose.

Q: What is the main research finding about Doral Tablets?

A: Clinical studies established the drug's effectiveness in placebo-controlled trials for the management of insomnia. These studies documented benefits for both difficulty falling asleep and problems with sleep maintenance over short-term (5-night) and intermediate-term (28-night) durations.

Q: Can Doral Tablets cause problems with memory?

A: Official warnings include reports of patients experiencing amnesia, which is a form of memory loss, following episodes of complex sleep behaviors. These behaviors can include actions like sleep-driving that occurred while the patient was not fully awake.

Q: Are allergic reactions to Doral Tablets a common concern?

A: Regulatory documents warn specifically about the occurrence of rare cases of severe allergic reactions, such as anaphylaxis (a severe, potentially life-threatening reaction) and angioedema (swelling). The frequency of milder allergic reactions is not commonly detailed in the official warnings.

Q: Is it possible to have an overdose on Doral Tablets?

A: Yes, official documents include a section describing Overdosage. Symptoms of an overdose may range in severity from drowsiness and confusion to more serious outcomes like coma and respiratory depression.

Q: What are the signs that Doral Tablets may not be working for someone?

A: Official regulatory warnings state that if the patient's insomnia does not improve within 7 to 10 days of starting treatment, this failure to respond may indicate the presence of an underlying medical condition that may require further evaluation.

Q: Does Doral Tablets contain any controlled substances?

A: The medicine's active ingredient, quazepam, is classified as a Schedule IV controlled substance. This classification is assigned due to documented risks of abuse, misuse, and dependence.

Q: What if I'm taking Doral Tablets and need to have surgery?

A: The drug is classified as a Central Nervous System (CNS) depressant and is a CYP2B6 inhibitor. These characteristics indicate the potential for additive effects with other CNS depressants, including certain forms of anesthesia used during surgical procedures.

How should Doral Tablets be stored and disposed of?

Storage and Disposal of Doral Tablets

Doral (quazepam) tablets must be stored at Controlled Room Temperature, which is officially maintained between 68 F and 77 F (20 C to 25 C). The medication should be protected from temperatures outside this range.

Child Safety and Security

As a Schedule IV controlled substance, Doral must be kept in a safe and secure place at all times to prevent misuse, theft, or accidental exposure. This includes the mandatory requirement that the tablets be kept out of the reach of children.

Disposal of Unused Medication

Any unused or expired Doral tablets must be disposed of promptly and safely. Disposal should follow the procedures established for controlled substances, such as utilizing authorized community drug take-back programs, to prevent diversion.

Doral Tablets